AU2007240860A1 - Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors - Google Patents

Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors Download PDF

Info

Publication number
AU2007240860A1
AU2007240860A1 AU2007240860A AU2007240860A AU2007240860A1 AU 2007240860 A1 AU2007240860 A1 AU 2007240860A1 AU 2007240860 A AU2007240860 A AU 2007240860A AU 2007240860 A AU2007240860 A AU 2007240860A AU 2007240860 A1 AU2007240860 A1 AU 2007240860A1
Authority
AU
Australia
Prior art keywords
alkyl
substituted
hydrogen
unsubstituted
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007240860A
Other languages
English (en)
Inventor
Benny C. Askew Jr.
Xiaoling Chen
Andreas Goutopoulos
Srinivasa Karra
Henry Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of AU2007240860A1 publication Critical patent/AU2007240860A1/en
Assigned to MERCK SERONO SA reassignment MERCK SERONO SA Alteration of Name(s) of Applicant(s) under S113 Assignors: LABORATOIRES SERONO SA
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007240860A 2006-04-19 2007-04-18 Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors Abandoned AU2007240860A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79307306P 2006-04-19 2006-04-19
US60/793,073 2006-04-19
PCT/US2007/009456 WO2007123936A1 (en) 2006-04-19 2007-04-18 Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors

Publications (1)

Publication Number Publication Date
AU2007240860A1 true AU2007240860A1 (en) 2007-11-01

Family

ID=38357968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007240860A Abandoned AU2007240860A1 (en) 2006-04-19 2007-04-18 Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors

Country Status (14)

Country Link
US (1) US8076486B2 (enExample)
EP (1) EP2013180A1 (enExample)
JP (1) JP5525812B2 (enExample)
KR (1) KR20090005195A (enExample)
CN (2) CN101426766B (enExample)
AR (1) AR060807A1 (enExample)
AU (1) AU2007240860A1 (enExample)
BR (1) BRPI0711625A2 (enExample)
CA (1) CA2644425A1 (enExample)
EA (1) EA200802050A1 (enExample)
IL (1) IL194546A0 (enExample)
MX (1) MX2008013308A (enExample)
WO (1) WO2007123936A1 (enExample)
ZA (1) ZA200807263B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
EP2231636B1 (en) * 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2014007228A1 (ja) 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
KR20170125931A (ko) * 2015-03-10 2017-11-15 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물
TN2017000483A1 (en) 2015-05-20 2019-04-12 Amgen Inc Triazole agonists of the apj receptor.
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
JP7245229B2 (ja) 2017-08-21 2023-03-23 ビバーチェ セラピューティクス，インク． ベンゾスルホニル化合物
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
EP3720430A4 (en) 2017-12-06 2021-05-05 Vivace Therapeutics, Inc. BENZOCARBONYL COMPOUNDS
BR112020011162A2 (pt) * 2017-12-07 2020-11-17 Amplyx Pharmaceuticals, Inc. agentes antifúngicos derivados de piridina substituída por heterociclo
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
EP3793551A4 (en) 2018-05-16 2022-01-26 Vivace Therapeutics, Inc. OXADIAZOLE COMPOUNDS
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
EP4061364A4 (en) * 2019-11-20 2023-09-13 Vivace Therapeutics, Inc. HETEROARYL COMPOUNDS
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
WO2025054260A1 (en) * 2023-09-07 2025-03-13 Kinnate Biopharma Inc. Inhibitors of mek kinase
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144215A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
GB2373245A (en) * 2001-03-12 2002-09-18 Bayer Ag Pyridinyl pyrazoles and their use for the treatment of COPD
CA2498281A1 (en) * 2002-09-10 2004-03-25 Pharmacia Italia S.P.A. Substituted pyridine derivatives as antitumor agent
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
AU2004229392A1 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
JP4768628B2 (ja) 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
PT1802579E (pt) * 2004-10-20 2014-02-17 Merck Serono Sa Derivados da 3-arilaminopiridina

Also Published As

Publication number Publication date
EP2013180A1 (en) 2009-01-14
MX2008013308A (es) 2008-10-27
ZA200807263B (en) 2009-11-25
US20070287737A1 (en) 2007-12-13
CN103121996B (zh) 2015-10-21
US8076486B2 (en) 2011-12-13
AR060807A1 (es) 2008-07-16
WO2007123936A1 (en) 2007-11-01
JP2009534386A (ja) 2009-09-24
CA2644425A1 (en) 2007-11-01
IL194546A0 (en) 2009-08-03
JP5525812B2 (ja) 2014-06-18
HK1127354A1 (en) 2009-09-25
EA200802050A1 (ru) 2009-04-28
KR20090005195A (ko) 2009-01-12
CN103121996A (zh) 2013-05-29
CN101426766A (zh) 2009-05-06
BRPI0711625A2 (pt) 2011-12-06
CN101426766B (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
AU2007240860A1 (en) Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors
AU2007272972B2 (en) Triazolyl pyridyl benzenesulfonamides as CCR2 or CCR9 modulators for the treatment of atherosclerosis
ES2791315T3 (es) Agonistas triazoles del receptor APJ
JP4441446B2 (ja) グルコキナーゼ化合物
CN119487041A (zh) 一类prmt5抑制剂及其用途
AU2018320418B2 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
BR112014021189B1 (pt) Composto, seu uso para a preparação de uma composição farmacêutica, e, composição farmacêutica contendo o mesmo
CZ299836B6 (cs) Aryl- a heteroaryl-substituované heterocyklické mocoviny, jejich použití a farmaceutické kompozice s jejich obsahem
MX2010013773A (es) Compuestos de 2,4'-bipiridinilo como inhibidores de cinasa d de proteina utiles para el tratamiento de, entre otras, insuficiencia cardiaca ia y cancer.
JP2021504317A (ja) ハロアリルアミン類のｓｓａｏ／ｖａｐ−１阻害剤とその用途
JP2010522241A (ja) 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
EA037162B1 (ru) 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj
JP2024056742A (ja) キノリン誘導体から調製される新規な阻害剤
EP1812425A2 (en) C-fms kinase inhibitors
JP2007505888A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
KR20230043103A (ko) 술폰아마이드 화합물
CN110437220B (zh) 三氮唑类化合物及其应用
CN107531645A (zh) 坏死性凋亡的抑制剂
WO2021127302A1 (en) 2-(1h-indole-3-carbonyl)-thiazole-4-carboxamide derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders
AU2017229129A1 (en) Thiazolidinone compounds and use thereof
JP2008545756A (ja) 癌化学療法剤として有用な１−メチル−１ｈ−ピラゾール−４−カルボキサミド類
TW201245187A (en) Pyrazole derivatives
AU2007209981A1 (en) Potassium channel inhibitors
CN103781765A (zh) 作为hdl-胆固醇升高剂的3-吡啶甲酰肼类
HK1127354B (en) Heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period